Zimmer Biomet (NYSE:ZBH) Earns Buy Rating from Argus

Zimmer Biomet (NYSE:ZBH)‘s stock had its “buy” rating reiterated by Argus in a report released on Thursday, Benzinga reports. They presently have a $125.00 price target on the medical equipment provider’s stock. Argus‘s price target would indicate a potential upside of 26.71% from the stock’s current price.

ZBH has been the subject of several other reports. Stifel Nicolaus lifted their target price on Zimmer Biomet from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. BMO Capital Markets restated a “market perform” rating on shares of Zimmer Biomet in a report on Monday, September 28th. Wall Street Zen downgraded Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Canaccord Genuity Group raised their price objective on Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a report on Monday, August 10th. Finally, Sanford C. Bernstein raised their price objective on Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a report on Thursday, August 6th. Seven investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $104.47.

Zimmer Biomet Trading Down 0.2%

Shares of ZBH stock traded down $0.16 during trading hours on Thursday, reaching $98.65. 2,016,767 shares of the stock were exchanged, compared to its average volume of 2,231,348. Zimmer Biomet has a 12-month low of $79.12 and a 12-month high of $104.15. The firm has a market capitalization of $18.82 billion, a price-to-earnings ratio of 24.00, a price-to-earnings-growth ratio of 1.79 and a beta of 0.49. The company’s 50-day moving average price is $95.13 and its 200-day moving average price is $91.52. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The business had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same period last year, the company earned $2.07 earnings per share. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, equities analysts anticipate that Zimmer Biomet will post 8.54 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Kevin R. Thornal sold 5,691 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Chad F. Phipps sold 3,000 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the sale, the insider directly owned 65,231 shares in the company, valued at $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.28% of the stock is owned by insiders.

Institutional Trading of Zimmer Biomet

Several institutional investors and hedge funds have recently bought and sold shares of ZBH. Tacita Capital Inc purchased a new stake in Zimmer Biomet in the second quarter valued at $26,000. Ancora Advisors LLC purchased a new position in Zimmer Biomet in the 2nd quarter valued at about $29,000. Elevation Wealth Partners LLC raised its stake in Zimmer Biomet by 145.9% in the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 229 shares during the last quarter. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zimmer Biomet in the first quarter valued at about $44,000. Finally, Parvin Asset Management LLC acquired a new position in shares of Zimmer Biomet during the 2nd quarter worth approximately $47,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.